Dr. Zandberg is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
5115 Centre Avenue
Pittsburgh, PA 15232Phone+1 412-641-1000Fax+1 412-641-1221- Is this information wrong?
Education & Training
- University of MarylandFellowship, Hematology and Medical Oncology, 2009 - 2012
- George Washington UniversityResidency, Internal Medicine, 2005 - 2008
- Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 2005
Certifications & Licensure
- PA State Medical License 2018 - 2024
- MD State Medical License 2012 - 2019
- VA State Medical License 2005 - 2010
- DC State Medical License 2005 - 2008
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery Start of enrollment: 2012 Aug 20
- Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2014 Oct 23
- Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck Start of enrollment: 2019 Jan 10
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsPatient, family caregiver, and economic outcomes of an integrated screening and novel stepped collaborative care intervention in the oncology setting in the USA (CARES...Jennifer L Steel, Charles J George, Lauren Terhorst, Jonathan G Yabes, Vincent Reyes, Dan P Zandberg, Marci Nilsen, Gauri Kiefer, Jonas Johnson, Christopher Marsh, Jas...> ;Lancet. 2024 Apr 6
- INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors.Hilton, J., Hansen, A., Mathew, M., Messina, C., Dave, V., Ji, X., Karpinich, N., Hirschfeld, S., Ballas, M., Ott, P., Li, Z., Zandberg, D.> ;Cancer Immunology, Immunotherapy. 2024 Feb 13
- PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: An open-label, phase I dose-expansion study.Rodriguez, C., Kang, H., Babbar, N., Sun, W., Ferrarotto, R., Swiecicki, P., Zandberg, D., Baiocchi, R., Wesolowski, R., McKean, M., Monga, V., Nath, R., Palmisiano, N...> ;Oral Oncology. 2024 Feb 1
- Join now to see all
Journal Articles
- Intratumor Genetic Heterogeneity in Squamous Cell Carcinoma of the Oral CavityScott E Strome, John C Papadimitriou, Dan P Zandberg, Head & Neck
Press Mentions
- OmniSeq and UPMC Collaborate to Launch Novel Phase II Prospective Head and Neck Cancer Clinical StudyJanuary 28th, 2021
- Hill Day Advocates Present Unified Voice in Support of NIH, NCI FundingMay 1st, 2019
- Gene-Guided Immunotherapy Misses Mark in Recurrent/Metastatic Head and Neck CancerMarch 5th, 2024
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
- UPMC Magee-Womens HospitalPittsburgh, Pennsylvania
- UPMC Presbyterian ShadysidePittsburgh, Pennsylvania
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: